Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program
Centessa Pharmaceuticals plc reported financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with the company expecting these funds to support operations into mid-2027. Research and development expenses were $41.6 million, up from $33.9 million in the same period in 2024. General and administrative expenses were $12.2 million, compared to $12.5 million for the third quarter of 2024. Net loss was $54.9 million, compared to a net loss of $42.6 million in the third quarter of 2024. During the period, Centessa advanced its OX2R agonist program, reporting Phase 2a data for ORX750 in narcolepsy and idiopathic hypersomnia and Phase 1 data for ORX142, with plans to initiate further studies in early 2026. ORX489 continues in IND-enabling studies, also targeting clinical study initiation in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569016-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.